|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 风雨不动 于 2012-4-14 14:53 编辑
<http://onlinelibrary.wiley.com/doi/10.1002/hep.24434/abstract>
Viral Hepatitis
Autologous bone marrow mesenchymal stem cell transplantation in liver
failure patients caused by hepatitis B: Short-term and long-term
outcomes†‡
Liang Peng1, Dong-ying Xie1, Bing-Liang Lin1, Jing Liu1, Hai-peng Zhu2,
Chan Xie1, Yu-bao Zheng1, Zhi-liang Gao1,*,§
Article first published online: 14 JUL 2011
DOI: 10.1002/hep.24434
Copyright © 2011 American Association for the Study of Liver Diseases
Issue
Hepatology
Volume 54, Issue 3, pages 820–828, 2 September 2011
Abstract
Our study aimed to investigate the short-term efficacy and long-term
prognosis of liver failure patients caused by hepatitis B after a single
transplantation with autologous marrow mesenchymal stem cells (MMSCs). A
total of 527 inpatients with liver failure caused by hepatitis B were
recruited and received the same medical treatments, among whom 53 patients
underwent a single transplantation with autologous MMSCs. A total of 105
patients matched for age, sex, and biochemical indexes, including alanine
aminotransferase (ALT), albumin, total bilirubin (TBIL), prothrombin time
(PT), and Model for End-Stage Liver Disease (MELD), comprised the control
group. A total of 120 mL of bone marrow was obtained from each patient and
then diluted and separated. Then, the MMSC suspension was slowly transfused
into the liver through the proper hepatic artery. The success rate of
transplantation was 100%, without serious side effects or complications.
Levels of ALB, TBIL, and PT and MELD score of patients in the
transplantation group were markedly improved from 2-3 weeks after
transplantation, compared with those in the control group. At 192 weeks of
follow-up, there were no dramatic differences in incidence of
hepatocellular carcinoma (HCC) or mortality between the two groups.
Additionally, there were no significant differences in the incidence of HCC
or mortality between patients with and without cirrhosis in the
transplantation group.
Conclusion: Autologous MMSC transplantation is safe for liver failure
patients caused by chronic hepatitis B. Short-term efficacy was favorable,
but long-term outcomes were not markedly improved. In respect to several
parameters, this method is preferable for patients with liver cirrhosis and
may have potential for reducing their incidence of HCC and mortality.
(HEPATOLOGY 2011;)
(6.合.彩).足球.篮球...各类投注开户下注
第一投注.现金网:招代理年薪10万以上:6668.cc |
|
发表于 2011-8-30 20:31